Product Name: Nek6 (203-209) pS206
Product Number: PE-04AOE99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: Nek6 (203-209) pS206

Product Use: Services as a blocking peptide for use with the Nek6-pS206 rabbit polyclonal antibody (Cat. No.: AB-PK734) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S206 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: AAH-pS-LVG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 906.94 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Nek6 - pS206 phosphosite-specific antibody (Cat. No.: AB-PK734)

Scientific Background: Nek6 is a protein-serine/threonine kinase that is a member of the Other group of protein kinases in the Nek family. This kinase is highly expressed and widely distributed in most tested human tissues except apparently in the brain and spinal cord. Nek6 is closely related in its catalytic domain to the protein-serine/threonine kinase NimA of Aspergillus nidulans. Nek6 is phosphorylated and activated during M phase of the cell cycle, and its inhibition facilitates apoptosis. Inhibition of Nek6 function by either overexpression of an inactive Nek6 mutant or elimination of endogenous Nek6 by siRNA arrests cells in M phase and triggers apoptosis. Nek6 may be an oncoprotein (OP). Nek6 may contribute to tumourigenesis by suppressing p53/TP53-induced cancer cell senescence. Nek6 inhibition sensitizes human cancer cells towards premature senescence.